Fidarestat (SNK 860) is an inhibitor of aldose reductase , with IC 50 s of 26 nM, 33 μM, and 1.8 μM for aldose reductase , AKR1B10 and V301L AKR1B10, respectively; Fidarestat (SNK 860) has the potential to treat diabetic disease. In Vitro Fidarestat is an inhibitor of aldose reductase, with IC 50 s of 26 nM, 33 μM, and 1.8 μM for aldose reductase, AKR1B10 and V301L AKR1B10, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Fidarestat (SNK-860; 1 or 4 mg/kg. p.o., daily for 4 weeks) reduces the concentrations of sorbitol and fructose in diabetic rats. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:IC50: 26 nM (Aldose reductase), 33 μM (AKR1B10), 1.8 μM (V301L AKR1B10)